Li, Dan;
Sabato, Philip E.;
Guiastrennec, Benjamin;
Ouerdani, Aziz;
Feng, Hwa-Ping;
Duval, Vincent;
De Anda, Carisa S.;
Sears, Pamela S.;
Chou, Margaret Z.;
Hardalo, Catherine;
Broyde, Natalya;
Rizk, Matthew L.
Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
Contributor:
Li, Dan;
Sabato, Philip E.;
Guiastrennec, Benjamin;
Ouerdani, Aziz;
Feng, Hwa-Ping;
Duval, Vincent;
De Anda, Carisa S.;
Sears, Pamela S.;
Chou, Margaret Z.;
Hardalo, Catherine;
Broyde, Natalya;
Rizk, Matthew L.
Published:
American Society for Microbiology, 2021
Published in:
Antimicrobial Agents and Chemotherapy, 65 (2021) 12
Description:
Tedizolid phosphate is an oxazolidinone antibacterial agent approved for the treatment of Gram-positive acute bacterial skin and skin structure infections (ABSSSIs) in patients aged ≥12 years. To support the use of tedizolid phosphate in adolescents with ABSSSIs, a population pharmacokinetic (PK) model, developed using adult and pediatric data, was updated to include PK data from a phase 3 clinical trial (PN012) that evaluated the safety and efficacy of once-daily oral or intravenous 200-mg tedizolid phosphate treatment in adolescents (12 to <18 years) with ABSSSIs, along with emerging data from a phase 1 trial (PN013) in children (2 to <12 years).